ArticleWorld journal of urology2026
Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort study.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChronic inflammation has been linked to oncogenesis, including in prostate cancer (PCa). Tumor Necrosis Factor (TNF) has been implicated in many of these chronic inflammatory pathways. We assessed urologic malignancy risk in patients with long-term exposure to TNF inhibitors (TNF-I).
methodsRetrospective non-matched cohort study of patients with chronic inflammatory conditions from 1996 to 2023. TNF-I exposure was identified using medications. The unmatched control cohort consisted of TNF-I-unexposed patients with the same chronic inflammatory conditions. Urologic malignancies identified using ICD-10 codes and manual chart review. Inverse Probability of Treatment Weighting was used to balance distributions across exposure groups. Hazard ratios (HR) were estimated using multivariable regression followed by logistic regression for relative risk (RR) on sub-analysis.
resultsThere were 13,377 patients with TNF-I exposure and 42,832 patients without TNF-I exposure. TNF-I exposure was negatively associated with PCa (HR 0.50, 95% CI 0.28–0.90, P = 0.02), but with higher Gleason grade group (RR 1.11, 95% CI 1.01–1.22, P = 0.04). TNF-I exposure was not associated with bladder cancer diagnosis (HR 0.71, 95% CI 0.26–1.95, P = 0.51) but had increased risk of multifocal tumor development (P = 0.001) and high-grade tumor (P = 0.004). TNF-I exposure was not associated with kidney cancer risk (HR 1.47, 95% CI 0.85–2.54, P = 0.17) but with increased risk of higher clinical stage (RR 2.01, 95% CI 1.21–3.33, P = 0.01).
conclusionTNF-I exposure was associated with lower risk of PCa but higher-grade group PCa. TNF-I exposure was associated with higher risk of multifocal and high-grade bladder cancer and of higher stage kidney cancer. TNF-I exposed patients may need modified urologic cancer screening. In this report, we looked at exposure to TNF inhibitor medications and their risk of prostate, bladder, and kidney cancer. We found that, compared to patients who did not take these medications, there was a lower risk of prostate cancer but with higher grade disease. There was no change in the overall risk of bladder or kidney cancer diagnosis, but they did have worse features. Further studies of patients on TNF inhibitors should be performed to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.